Content Title

  • MSKCC
  • The Rockefeller University
  • Weill Cornell Medical College

News

  • June 7-12, 2015

    Drew LogoThe Drew University 29th Annual ResMed:
    Residential School on Medicinal Chemistry and Biology in Drug Discovery

    • A week-long graduate level, accelerated program on the fundamentals of drug discovery from initial target validation through clinical development.
    • Sessions are led by leaders in the field from Bristol-Meyers Squibb, Eli Lilly, Genzyme, GlaxoSmithKline, Merck, Novartis, Pfizer, Vanderbilt University, etc.
    • Designed for medicinal chemists, biologists and other industrial/academic scientists.
    • Sessions will be live-streamed from Drew University to the Weill Cornell campus.

    View complete schedule.

    The Tri-I TDI will be providing free access to this class, via streaming, to the Tri-I Community. The class size will be limited, so watch your in-box for the opportunity to enroll.

  • September 9, 2014 The Weill Cornell Medical College presents the MILSTEIN PROGRAM IN MEDICINAL CHEMISTRY SYMPOSIUM: FROM TARGET TO TREATMENT
    More
  • Tri-Institutional Therapeutics Discovery Institute, Inc. October 1, 2013 Tri-Institutional Therapeutics Discovery Institute, Inc. Launched by Memorial Sloan-Kettering Cancer Center, The Rockefeller University and Weill Cornell Medical College, and Partnership Formed with Takeda
    More

Partners

Takeda

Takeda Pharmaceutical
Company Limited


A global, research-based pharmaceutical company with a strong record for bringing new medicines to market, Takeda will provide medicinal chemists and pharmacologists to work on the development of small molecules.

Facebook iconTwitter iconLinked In icon

 

 

NewsJune 7-12, 2015The Drew University 29th Annual ResMed: Residential School on Medicinal Chemistry and Biology in Drug DiscoveryA week-long graduate level, accelerated program on the f